AI주식인사이트AI Stock Insight
D

바이넥스

053030KOSDAQ의약품 제조업

35.0 / 100

Reference Date: 2026-07-24

Financial Score8.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Declined 10.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Bionex is a biopharmaceutical CDMO company that produces chemical pharmaceuticals at its Busan factory and expanded production capacity threefold with a new facility in 2023. Its chemical business unit focuses on ointments and eye drops, securing market share with proprietary products, while biopharmaceutical CDMO services accounted for 46.72% of revenue in 2025. The company has established cGMP-compliant systems and passed global GMP inspections to grow as a global CDMO.

Number of Employees

791people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.234.0Point
PBR
1.15Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE
-1.78Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
32.71Industry Average 12.430.0Point

2.6x industry avg (risky)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼1482.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -6.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 6,600Won52-week high 18,49052-week low 6,350
1-month return1.0Point

1m -10.20% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-07-03